United Kingdom· GB-APID-41611111000001101
Oxlumo 94.5mg/0.5ml solution for injection vials
A lumasiran product containing lumasiran, registered in United Kingdom by Alnylam UK Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lumasiran is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AX18 (lumasiran), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Lumasiran · ATC A16AX18
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lumasiran
- Manufacturer
- Alnylam UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- A16AX18
- ATC class
- Lumasiran
- Defined daily dose
- 2.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lumasiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaOXLUMOALNYLAM NETHERLANDS B.V.
- SwitzerlandOxlumo 94.5 mg / 0.5 ml, InjektionslösungAlnylam Switzerland GmbH
- SpainOXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLEAlnylam Netherlands B.V.
- FranceOXLUMO 94,5 mg/0,5mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- IcelandOxlumoAlnylam Netherlands B.V.
- NetherlandsOxlumo 189 mg/ml, oplossing voor injectieAlnylam Netherlands B.V.
- PolandOxlumoAlnylam Netherlands B.V.
- SwedenOxlumo 94,5 mg/0,5 ml Injektionsvätska, lösningAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Oxlumo
- Liechtenstein · Oxlumo
- Norway · Oxlumo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b818e988-1226-4c6d-993f-c171d8ec6fb7 GET /v1/drugs/b818e988-1226-4c6d-993f-c171d8ec6fb7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "41611111000001101",
"desc": "Oxlumo 94.5mg/0.5ml solution for injection vials (Alnylam UK Ltd)",
"form": "Solution for injection",
"vpid": "41868711000001101",
"source": "dmd",
"vtm_id": "1137590006",
"strength": "189 mg",
"substance": "Lumasiran",
"ingredient": "Lumasiran sodium",
"supplier_code": "37334111000001102"
}See everything about lumasiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.